文献速递心脑血管急症消化、代谢与肾脏急症

外周动脉血运重建后利伐沙班的应用

Rivaroxaban in Peripheral Artery Disease after Revascularization.
PubMed 文献 · N Engl J Med · 2020-03-28
一句话结论下肢血运重建后外周动脉疾病患者,利伐沙班2.5 mg每日两次联合阿司匹林较单用阿司匹林显著降低急性肢体缺血、大截肢、心梗、缺血性卒中或心血管死亡复合终点发生率。

VOYAGER PAD双盲试验纳入6564例外周动脉疾病且接受下肢血运重建的患者,随机接受利伐沙班2.5 mg每日两次联合阿司匹林或安慰剂联合阿司匹林。主要疗效终点为急性肢体缺血、血管原因大截肢、心肌梗死、缺血性卒中或心血管死亡的复合终点,3年Kaplan-Meier估计发生率利伐沙班组17.3% vs 安慰剂组19.9%(HR 0.85,95%CI 0.76-0.96,P=0.009)。TIMI大出血两组无显著差异(2.65% vs 1.87%,HR 1.43,95%CI 0.97-2.10,P=0.07),ISTH大出血利伐沙班组显著更高(5.94% vs 4.06%,HR 1.42,95%CI 1.10-1.84,P=0.007)。

要点

  • 下肢血运重建后外周动脉疾病患者,利伐沙班2.5 mg每日两次联合阿司匹林较单用阿司匹林降低3年主要复合终点(17.3% vs 19.9%,HR 0.85,95%CI 0.76-0.96,P=0.009)。
  • TIMI大出血利伐沙班联合组2.65% vs 单用阿司匹林组1.87%,无显著差异(HR 1.43,95%CI 0.97-2.10,P=0.07)。
  • ISTH大出血利伐沙班联合组5.94% vs 单用阿司匹林组4.06%,显著更高(HR 1.42,95%CI 1.10-1.84,P=0.007)。
  • 主要疗效终点包含急性肢体缺血、血管原因大截肢、心肌梗死、缺血性卒中或心血管死亡。

适用人群与场景

  • 外周动脉疾病且已接受下肢血运重建的患者。

处置流程与药物剂量

  • 利伐沙班2.5 mg每日两次联合阿司匹林(利伐沙班组)。

研究设计与关键结果

  • 双盲试验,6564例患者随机分配,利伐沙班组3286例、安慰剂组3278例。
  • 主要疗效终点(急性肢体缺血、血管原因大截肢、心肌梗死、缺血性卒中或心血管死亡复合终点)利伐沙班组508例 vs 安慰剂组584例;3年Kaplan-Meier估计发生率17.3% vs 19.9%(HR 0.85,95%CI 0.76-0.96,P=0.009)。
  • TIMI大出血利伐沙班组62例 vs 安慰剂组44例(2.65% vs 1.87%;HR 1.43,95%CI 0.97-2.10,P=0.07)。
  • ISTH大出血利伐沙班组140例 vs 安慰剂组100例(5.94% vs 4.06%;HR 1.42,95%CI 1.10-1.84,P=0.007)。

证据类型、等级与局限

  • 证据类型:双盲随机对照试验(VOYAGER PAD,NCT02504216)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于外周动脉疾病且接受下肢血运重建的患者,利伐沙班2.5 mg每日两次联合阿司匹林较单用阿司匹林降低主要复合终点发生率,但ISTH大出血发生率显著更高。

指南或共识出处

  • VOYAGER PAD试验(NCT02504216),由Bayer和Janssen Pharmaceuticals资助。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with peripheral artery disease who have undergone lower-extremity revascularization are at high risk for major adverse limb and cardiovascular events. The efficacy and safety of rivaroxaban in this context are uncertain.

METHODS: In a double-blind trial, patients with peripheral artery disease who had undergone revascularization were randomly assigned to receive rivaroxaban (2.5 mg twice daily) plus aspirin or placebo plus aspirin. The primary efficacy outcome was a composite of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes. The principal safety outcome was major bleeding, defined according to the Thrombolysis in Myocardial Infarction (TIMI) classification; major bleeding as defined by the International Society on Thrombosis and Haemostasis (ISTH) was a secondary safety outcome.

RESULTS: A total of 6564 patients underwent randomization; 3286 were assigned to the rivaroxaban group, and 3278 were assigned to the placebo group. The primary efficacy outcome occurred in 508 patients in the rivaroxaban group and in 584 in the placebo group; the Kaplan-Meier estimates of the incidence at 3 years were 17.3% and 19.9%, respectively (hazard ratio, 0.85, 95% confidence interval [CI], 0.76 to 0.96; P = 0.009). TIMI major bleeding occurred in 62 patients in the rivaroxaban group and in 44 patients in the placebo group (2.65% and 1.87%; hazard ratio, 1.43; 95% CI, 0.97 to 2.10; P = 0.07). ISTH major bleeding occurred in 140 patients in the rivaroxaban group, as compared with 100 patients in the placebo group (5.94% and 4.06%; hazard ratio, 1.42; 95% CI, 1.10 to 1.84; P = 0.007).

CONCLUSIONS: In patients with peripheral artery disease who had undergone lower-extremity revascularization, rivaroxaban at a dose of 2.5 mg twice daily plus aspirin was associated with a significantly lower incidence of the composite outcome of acute limb ischemia, major amputation for vascular causes, myocardial infarction, ischemic stroke, or death from cardiovascular causes than aspirin alone. The incidence of TIMI major bleeding did not differ significantly between the groups. The incidence of ISTH major bleeding was significantly higher with rivaroxaban and aspirin than with aspirin alone. (Funded by Bayer and Janssen Pharmaceuticals; VOYAGER PAD ClinicalTrials.gov number, NCT02504216.).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Bonaca MP, Bauersachs RM, Anand SS, et al. Rivaroxaban in Peripheral Artery Disease after Revascularization. N Engl J Med. 2020. PMID: 32222135. doi:10.1056/NEJMoa2000052

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。